Ysios Capital has participated in a $102 million funding round for Neurona Therapeutics to advance the clinical trial of its innovative epilepsy treatment, NRTX-1001.

Target Information

Neurona Therapeutics, a biopharmaceutical company focused on developing regenerative cell therapies, has successfully closed an oversubscribed private financing round of $102 million. This funding, which saw participation from prestigious international investors such as Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, and Cormorant Asset Management, will pave the way for advancing clinical trials aimed at treating drug-resistant mesial temporal lobe epilepsy (MTLE). The proceeds will support the initiation of the pivotal Phase 3 EPIC study with NRTX-1001 and further the development of their innovative regenerative cell therapy platforms.

This financing round comes just 14 months after Neurona raised $120 million in its previous funding round, during which Ysios Capital joined as an investor. The quick follow-up funding underscores the significant clinical and strategic progress that Neurona has achieved, paving the way for potentially groundbreaking treatments in neurology.

Industry Overview in Spain

The biotech sector in Spain has experienced significant growth in recent years, demonstrating a robust environment for innovation and investment. With a growing number of biopharmaceutical firms present, Spain is emerging as a key player in the European